3 latest FDA approvals

Here are the three latest drugs approved by the FDA since June 1.

1. Mylan's drug Fulphila represents the first biosimilar version of Amgen's Neulasta, both of which boost white blood cell count to reduce infection risk in cancer patients undergoing chemotherapy.

2. Rituxan is the first treatment approved for moderate-to-severe pemphigus vulgaris, a rare autoimmune disease characterized by painful blistering on the skin and mucous membranes.

3. Mircera may now be used to treat chronic kidney disease-associated anemia in children.

More articles on supply chain:

How University of Washington Medical Center improved supply chain efficiency and saved $1M+
3 ways to understand healthcare supply chain in a changing market
Fitch: New drug approvals off pace from 2017

 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars